Dextromethorphan and memantine after ketamine analgesia: a randomized control trial.


Journal

Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745

Informations de publication

Date de publication:
2019
Historique:
received: 02 03 2019
accepted: 05 06 2019
entrez: 27 8 2019
pubmed: 27 8 2019
medline: 9 4 2020
Statut: epublish

Résumé

Intravenous ketamine is often prescribed in severe neuropathic pain. Oral A multicenter randomized controlled clinical trial included 60 patients after ketamine infusion for refractory neuropathic pain. Dextromethorphan (90 mg/day), memantine (20 mg/day) or placebo was given for 12 weeks (n=20 each) after ketamine infusion. The primary endpoint was pain intensity at one month. Secondary endpoints included pain, sleep, anxiety, depression, cognitive function and quality of life evaluations up to 12 weeks. At 1 month, dextromethorphan maintained ketamine pain relief (Numeric Pain Scale: 4.01±1.87 to 4.05±2.61, Oral dextromethorphan given after ketamine infusion extends pain relief during one month and could help patients to better cope with pain. Future studies should include larger populations stratified on pharmacogenetics screening. Optimization of an oral drug that could extend ketamine antihyperalgesia, with fewer hospital admissions, remains a prime challenge in refractory neuropathic pain.

Identifiants

pubmed: 31447547
doi: 10.2147/DDDT.S207350
pii: 207350
pmc: PMC6683947
doi:

Substances chimiques

Ketamine 690G0D6V8H
Dextromethorphan 7355X3ROTS
Memantine W8O17SJF3T

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

2677-2688

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

J Pharmacol Exp Ther. 1999 May;289(2):1060-6
pubmed: 10215688
Eur J Pain. 1998;2(4):321-327
pubmed: 10700327
J Pain Symptom Manage. 2001 Oct;22(4):834-42
pubmed: 11576800
Pain. 2002 Apr;96(3):261-7
pubmed: 11972998
Anesthesiology. 2002 May;96(5):1053-61
pubmed: 11981142
BMC Med Res Methodol. 2002 Jun 17;2:8
pubmed: 12069695
Pain. 2003 Feb;101(3):229-35
pubmed: 12583865
Acta Anaesthesiol Scand. 2004 Mar;48(3):328-36
pubmed: 14982566
Pain. 2004 Mar;108(1-2):129-36
pubmed: 15109516
Anesthesiology. 2005 Jan;102(1):211-20
pubmed: 15618805
Addict Biol. 2005 Dec;10(4):325-7
pubmed: 16318953
Am J Psychiatry. 2006 Jan;163(1):153-5
pubmed: 16390905
Eur J Pain. 2007 Apr;11(3):299-308
pubmed: 16716615
Neurology. 2007 Apr 10;68(15):1178-82
pubmed: 17420400
Pain Med. 2008 Mar;9(2):253-7
pubmed: 18298710
Eur J Pain. 2009 May;13(5):497-505
pubmed: 18783971
Pain. 2009 Oct;145(3):304-11
pubmed: 19604642
Anesthesiology. 2009 Oct;111(4):892-903
pubmed: 19741495
Eur J Pain. 2011 Mar;15(3):258-67
pubmed: 20638877
Indian J Anaesth. 2010 Mar;54(2):157-9
pubmed: 20661356
Epidemiology. 1990 Jan;1(1):43-6
pubmed: 2081237
Expert Rev Clin Pharmacol. 2011 May;4(3):379-88
pubmed: 21686074
Pain Med. 2012 Feb;13(2):263-9
pubmed: 21939497
Br J Clin Pharmacol. 2012 Aug;74(2):304-14
pubmed: 22295895
Pain Med. 2012 Feb;13(2):243-54
pubmed: 22314263
Minerva Anestesiol. 2012 Jul;78(7):757-66
pubmed: 22441361
Xenobiotica. 2012 Nov;42(11):1076-87
pubmed: 22612619
Eur J Pharmacol. 2013 Jan 5;698(1-3):228-34
pubmed: 23183107
Pain Physician. 2013 Jan;16(1):45-56
pubmed: 23340533
Clin Pharmacokinet. 2013 Mar;52(3):211-23
pubmed: 23371894
Pharmacol Rep. 2012;64(6):1560-6
pubmed: 23406767
Br J Clin Pharmacol. 2014 Feb;77(2):357-67
pubmed: 23432384
Pain. 2014 Apr;155(4):654-62
pubmed: 24291734
PLoS One. 2014 Feb 28;9(2):e89985
pubmed: 24587167
Rev Invest Clin. 2013 Sep-Oct;65(5):445-54
pubmed: 24687344
Contemp Clin Trials. 2014 Jul;38(2):314-20
pubmed: 24948402
Neuropharmacology. 2016 Mar;102:72-9
pubmed: 26519901
BMC Anesthesiol. 2016 Feb 18;16:12
pubmed: 26892406
Clin Pharmacokinet. 2016 Sep;55(9):1059-77
pubmed: 27028535
PLoS One. 2016 Apr 06;11(4):e0152741
pubmed: 27050431
J Pharmacokinet Biopharm. 1987 Jun;15(3):241-53
pubmed: 3668802
Pharmacogenetics. 1996 Aug;6(4):351-5
pubmed: 8873221
Am J Hum Genet. 1997 Feb;60(2):284-95
pubmed: 9012401
Neurology. 1997 May;48(5):1212-8
pubmed: 9153445

Auteurs

Elodie Martin (E)

Université Clermont Auvergne, Pharmacologie Fondamentale Et Clinique de la Douleur, Neuro-Dol, Inserm 1107, F-63000 Clermont-Ferrand, France.

Marc Sorel (M)

Centre D'evaluation et de Traitement de la Douleur/soins Palliatifs, Nemours, France.

Véronique Morel (V)

CHU Clermont-Ferrand, Centre de Pharmacologie Clinique/Centre d'investigation Clinique Inserm 1405, F-63003 Clermont-Ferrand cedex, France.

Fabienne Marcaillou (F)

Centre d'Evaluation et de Traitement de la Douleur, CHU de Clermont-Ferrand, France.

Pascale Picard (P)

Centre d'Evaluation et de Traitement de la Douleur, CHU de Clermont-Ferrand, France.

Noémie Delage (N)

Centre d'Evaluation et de Traitement de la Douleur, CHU de Clermont-Ferrand, France.

Florence Tiberghien (F)

Centre d'evaluation et de Traitement de la Douleur/soins Palliatifs, CHU Jean Minjoz, Besançon, France.

Marie-Christine Crosmary (MC)

Centre d'evaluation et de Traitement de la Douleur, CH Jacques Lacarin Vichy, France.

Mitra Najjar (M)

Centre d'evaluation et de Traitement de la Douleur, CH Jacques Lacarin Vichy, France.

Renato Colamarino (R)

Centre d'evaluation et de Traitement de la Douleur, CH Jacques Lacarin Vichy, France.

Christelle Créach (C)

Centre d'evaluation et de Traitement de la Douleur, CHU de Saint-etienne, France.
Inserm U1028 & Umr 5292, Centre de Neurosciences de Lyon, Université Lyon & Jean-monnet De Saint-etienne, France.

Béatrice Lietar (B)

Centre d'evaluation et de Traitement de la Douleur, CHU de Saint-etienne, France.

Géraldine Brumauld de Montgazon (G)

Centre d'evaluation et de Traitement de la Douleur/soins Palliatifs, CH La Rochelle, France.

Anne Margot-Duclot (A)

Centre d'evaluation et de Traitement de la Douleur, Fondation A de Rothschild, Paris, France.

Marie-Anne Loriot (MA)

Service de biochimie, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France.
Inserm UMR-S 1147, Université Paris Descartes, Paris, France.

Céline Narjoz (C)

Service de biochimie, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France.
Inserm UMR-S 1147, Université Paris Descartes, Paris, France.

Céline Lambert (C)

CHU Clermont-Ferrand, Délégation Recherche Clinique & Innovation - Villa annexe IFSI, 58 Rue Montalembert, F-63003 Clermont-Ferrand cedex, France.

Bruno Pereira (B)

CHU Clermont-Ferrand, Délégation Recherche Clinique & Innovation - Villa annexe IFSI, 58 Rue Montalembert, F-63003 Clermont-Ferrand cedex, France.

Gisèle Pickering (G)

Université Clermont Auvergne, Pharmacologie Fondamentale Et Clinique de la Douleur, Neuro-Dol, Inserm 1107, F-63000 Clermont-Ferrand, France.
CHU Clermont-Ferrand, Centre de Pharmacologie Clinique/Centre d'investigation Clinique Inserm 1405, F-63003 Clermont-Ferrand cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH